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Progressive multifocal leukoencephalopathy (PML) is a
demyelinating disease of the brain caused by the reactiva-
tion of the human polyomavirus JC (JCV), which occurs
in the setting of immunosuppression. Individuals at risk
of developing PML include patients with AIDS or lympho-
proliferative disorders, organ transplant recipients, and
patients treated with immunosuppressive or immu-
nomodulatory therapies for inflammatory or autoim-
mune diseases.
JCV remains latent in kidneys and lymphoid organs, and
reaches the brain via hematogenous route. There, JCV
causes a productive and lytic infection of oligodendro-
cytes leading to areas of demyelination and associated
neurologic deficits. PML was recognized and named fifty
years ago, before the discovery of its etiologic agent, and
before the availability of modern neuroimaging
techiques. However, we now recognize that PML may not
always be progressive, that it can present as a single lesion,
that it may not be restricted to the white matter, and that
it may harbor inflammatory features. Therefore, JCV
encephalopathy may be a more appropriate term to
describe all the facets of this disease.
Indeed, while the classic presentation of PML is devoid of
inflammation, novel inflammatory forms of PML have
been observed in the context of an immune reconstitution
inflammatory syndrome (IRIS), in HIV+ patients receiving
highly active antiretroviral therapy (HAART). This inflam-
matory reaction, characterized by contrast enhancement
of PML lesions on MRI and inflammatory infiltrates in the
brain parenchyma, may be associated with life-threaten-
ing edema and may require treatment with corticoster-
oids.
Moreover, in addition to glial cells, JCV can also infect cer-
ebellar granule cell neurons (GCN), leading to cerebellar
atrophy and associated cerebellar dysfunction in immu-
nosuppressed individuals. This novel clinical entity, dys-
tinct from PML, was named JCV granule cell
neuronopathy (JCV GCN). A deletion in the carboxy-ter-
minus of the VP1 gene, encoding the major viral capsid
protein, appears to be associated with the GCN tropism of
JCV.
There is no treatment for PML, and survival at one year
does not exceed 50%. However, individuals who are able
to mount a cellular immune response against JCV, medi-
ated by CD8+ cytotoxic T lymphocytes (CTL), have a pro-
longed survival and a better clinical outcome. These CTL
could be detected in the blood and CSF of PML survivors.
Furthermore, CD8+ T cells are present in PML lesions, and
aggregate around JCV-infected glial cells. Therefore,
immunotherapies aiming at boosting JCV-specific cellular
immune response, such as dendritic-cell based immuno-
therapy, may be a valid treatment option for PML.
Supported by NIH NINDS grants R01 041198 and
047029, R21 051124 and K24 060950 to IJK.
from Infectious diseases of the nervous system: pathogenesis and worldwide impact
Paris, France. 10–13 September 2008
Published: 23 September 2008
BMC Proceedings 2008, 2(Suppl 1):S23
<supplement> <title> <p>Infectious diseases of the nervous system: pathogenesis and worldwide impact</p> </title> <editor>Roberto Bruzzone, Monique Dubois-Dalcq, Georges E Grau, Diane E Griffin and Krister Kristensson</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1753-6561-2-S1-full.pdf">here</a>.</note> </supplement>
This abstract is available from: http://www.biomedcentral.com/1753-6561/2/S1/S23
© 2008 Koralnik; licensee BioMed Central Ltd. 
